Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 14, 2023 - Issue
Submit an article Journal homepage
400
Views
0
CrossRef citations to date
0
Altmetric
COMMENTARY

CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code

Shannon S Zhang1 University of California Irvine School of Medicine, Orange, CA, USAORCID Iconhttps://orcid.org/0000-0003-3157-5598
ORCID Icon,
Alexandria Lee1 University of California Irvine School of Medicine, Orange, CA, USAORCID Iconhttps://orcid.org/0000-0002-2618-8131
ORCID Icon &
Misako Nagasaka1 University of California Irvine School of Medicine, Orange, CA, USA;2 St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5308-615X
ORCID Icon
Pages 27-30 | Received 03 Jan 2023, Accepted 04 Apr 2023, Published online: 19 Apr 2023

References

  • Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14(18):5731–5734. doi:10.1158/1078-0432.CCR-08-0646
  • Lanman BA, Allen JR, Allen GJ, et al. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors. J Med Chem. 2020;63:52–65. doi:10.1021/acs.jmedchem.9b01180
  • Center for drug evaluation and research application number 214665Orig1s000. Drug Approval Package: Lumakras; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000TOC.cfm. Accessed August 16, 2021.
  • Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumor immunity. Nature. 2019;575:217–223. doi:10.1038/s41586-019-1694-1
  • Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. NEJM. 2020;383(13):1207–1217. doi:10.1056/NEJMoa1917239
  • Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. NEJM. 2021;384(25):2371–2381. doi:10.1056/NEJMoa2103695
  • Johnson ML, Johannes de Langen A, Waterhouse D, et al. Sotorasib versus Docetaxel For Previously Treated Non-Small Cell Lung Cancer with KRAS G12C mutation: CodeBreak 200 Phase 3 Study. ESMO Congress. 2022;401(10378):733–746.
  • Leighl N. Beyond chemotherapy – every step counts. ESMO congress; 2022.
  • Sabari JK, Park H, Tolcher AW, et al. KRYSTAL-1: a phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation. J Clin Oncol. 2021;39:TPS146–TPS146. doi:10.1200/JCO.2021.39.3_suppl.TPS146
  • Zhang SS, Nagasaka M. Spotlight on sotorasib (AMG 510) for KRASG12C positive non-small cell lung cancer. Lung Cancer. 2021;12:115–122. doi:10.2147/LCTT.S334623
  • Begum P, Goldin RD, Possamai LA, Popat S. Severe immune checkpoint inhibitor hepatitis in KRAS G12C-mutant NSCLC potentially triggered by sotorasib: case report. JTO Clin Case Rep. 2021;2(9):100213.
  • Gandara. AACR-NCI-EORTC conference; 2021.
  • Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021;16(8):1321–1332. doi:10.1016/j.jtho.2021.04.015
  • Loong HH, Du N, Cheng C. KRAS G12C mutations in Asia: a landscape analysis of 11.951 Chinese tumor samples. Transl Lung Cancer Res. 2020;9:5. doi:10.21037/tlcr-20-455
  • Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, Phase 2 trial. Lancet Oncol. 2022;23(1):115–124. doi:10.1016/S1470-2045(21)00605-7

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.